$XBI $64.37 | -8.21%
Table of Contents:
Covid Updates
$
Pipeline Updates
$PRAX -8.5% PRAXIS PRECISION MEDICINES REPORTS POSITIVE TOPLINE RESULTS FROM PRAX-944 PHASE 2A STUDY IN ESSENTIAL TREMOR PATIENTS source
$ACIU -12.3% AC Immune’s Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology. source
$OPK -6.9% OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases. source
$DCTH -6.9% Delcath Announces Poster Presentation at the 2022 ASCO Annual Meeting. source
$HUMA -9.2% Humacyte to Provide Human Acellular Vessels™ (HAVs™) to Front-line Hospitals in Ukraine for Treatment of Vascular Trauma Injuries. source
$LOGC +34.4% LogicBio Therapeutics Announces FDA Lifts Clinical Hold on SUNRISE Trial in Pediatric Patients with Methylmalonic Acidemia. source
$IMGO -5.9% Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Study of Bomedemstat in Combination with Atezolizumab in Small Cell Lung Cancer. source
$ELDN -7.1% Eledon Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy. source
$MREO -31.3% Mereo BioPharma announces Positive Top-Line Efficacy and Safety Data from “ASTRAEUS” Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency- associated Emphysema. source
$PRQR -9.0% ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022. source
$ALKS -3.7% Alkermes Announces Four Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. source
$CMPS -11.3% COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults. source
$ATHA -3.9% Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease. source
$OBSV -18.3% ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at the 2022 ACOG Annual Clinical and Scientific Meeting. source
$ACHL -9.3% Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma. source
Want to get weekly catalyst updates?
*We never spam you - unsubscribe anytime*
Business Updates
$HZNP -4.1% Horizon Therapeutics and Chicago Sky Announce Multi-Year Partnership source
$AXSM -10.1% Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea. source
$JAZZ -7.1% Jazz Pharmaceuticals Completes U.S. Divestiture of Sunosi® (solriamfetol) to Axsome Therapeutics. source
$MYOV -10.4% Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe. source
Posted by FS/JM
Comments